GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » Price-to-Owner-Earnings
中文

BioPlus Acquisition (BioPlus Acquisition) Price-to-Owner-Earnings : (As of Apr. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is BioPlus Acquisition Price-to-Owner-Earnings?

As of today (2024-04-25), BioPlus Acquisition's share price is $10.795. BioPlus Acquisition does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for BioPlus Acquisition's Price-to-Owner-Earnings or its related term are showing as below:


BIOS's Price-to-Owner-Earnings is not ranked *
in the Diversified Financial Services industry.
Industry Median: 9.02
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-25), BioPlus Acquisition's share price is $10.795. BioPlus Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.21. Therefore, BioPlus Acquisition's PE Ratio for today is 52.15.

As of today (2024-04-25), BioPlus Acquisition's share price is $10.795. BioPlus Acquisition's EPS without NRI for the trailing twelve months (TTM) ended in was $0.21. Therefore, BioPlus Acquisition's PE Ratio without NRI for today is 52.15.

During the past 2 years, BioPlus Acquisition's highest PE Ratio without NRI was 870.83. The lowest was 0.00. And the median was 0.00.


BioPlus Acquisition Price-to-Owner-Earnings Historical Data

The historical data trend for BioPlus Acquisition's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPlus Acquisition Price-to-Owner-Earnings Chart

BioPlus Acquisition Annual Data
Trend Dec21 Dec22
Price-to-Owner-Earnings
- -

BioPlus Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioPlus Acquisition's Price-to-Owner-Earnings

For the Shell Companies subindustry, BioPlus Acquisition's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPlus Acquisition's Price-to-Owner-Earnings Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where BioPlus Acquisition's Price-to-Owner-Earnings falls into.



BioPlus Acquisition Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

BioPlus Acquisition's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=10.795/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioPlus Acquisition  (NAS:BIOS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


BioPlus Acquisition Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of BioPlus Acquisition's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPlus Acquisition (BioPlus Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
260 Madison Avenue, Suite 800, New York, NY, USA, 10026
Website
BioPlus Acquisition Corp is a blank check company.
Executives
Steven C. Fletcher 10 percent owner C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807
Explorer Parent Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Founder Holdings Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Alex Serge Vieux 10 percent owner C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749
Bioplus Sponsor Llc 10 percent owner 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Louis G Lange director 3172 PORTER DRIVE, PALO ALTO CA 94034
Ross Haghighat director, officer: CEO and CFO C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Ronald W Eastman director 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Shawn Cross director 1825 K STREET SUITE 510, WASHINGTON DC 20006
Jonathan Rigby director, officer: Chief Business Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Glen Giovannetti director UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000